Skip to content
You are now leaving https://www.ionispharma.com to visit

First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting

Wholly-owned LICA drug for beta-thalassemia, IONIS-TMPRSS6-L Rx, demonstrates therapeutic potential with positive modulation of important disease-related biomarkers and increase of serum hepcidin in initial clinical study Ionis oncology research to be recognized with American Society of Hematology